In The News

    Feed has no items.

Myeloma Research News The Web’s Daily Resource for Myeloma Research News

  • Investigational Antibody GBR 1342 Receives Orphan Drug Designation for Multiple Myeloma
    by Alejandra Viviescas, PhD. on September 20, 2019 at 12:46 pm

    GBR 1342, an investigational bispecific antibody developed by Glenmark Pharmaceuticals, was granted orphan drug designation by the U.S Food and Drug Administration (FDA) for the treatment of multiple myeloma patients who have received prior therapies. The FDA’s Office of Orphan Products Development (OOPD) gives this designation to novel therapies intended to improve the treatment and management […] The post Investigational Antibody GBR 1342 Receives Orphan Drug Designation for Multiple Myeloma appeared first on Myeloma Research News.

  • Ygalo Continues to Show Promising Activity in Relapsed, Refractory Multiple Myeloma
    by Joana Carvalho, MSc on September 18, 2019 at 10:53 am

    Ygalo (melflufen) combination therapy continues to demonstrate promising results, without significant side effects, in patients with relapsed or refractory multiple myeloma, updated data from two clinical trials show. The findings were presented at the Society of Hematologic Oncology (SOHO) 2019 Annual Meeting, held Sept. 11–14 in Houston, Texas. Ygalo is a lipophilic peptide-conjugated alkylator developed […] The post Ygalo Continues to Show Promising Activity in Relapsed, Refractory Multiple Myeloma appeared first on Myeloma Research News.

  • Researchers Identify Promising Target for CAR T-cell Therapy in Myeloma
    by Marta Figueiredo on September 13, 2019 at 1:33 pm

    Designing CAR T-cells to specifically target GPRC5D — a protein appreciably present on the surface of myeloma cells — may be a safe and effective therapy against multiple myeloma, a preclinical study shows. The study, “GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells,” was published in the journal […] The post Researchers Identify Promising Target for CAR T-cell Therapy in Myeloma appeared first on Myeloma Research News.

  • Cancer Patients Around the World to Receive Henry Schein ‘Comfort Kits’
    by Patricia Inacio, PhD on September 11, 2019 at 12:32 pm

    Henry Schein, a foundation devoted to promoting dental and medical health, has produced more than 27,000 comfort kits for people fighting cancer in the U.S. The kits, which are meant to make patients feel at home while receiving care away from home, were assembled by more than 2,100 Team Schein Members (TSM) globally. They will be given […] The post Cancer Patients Around the World to Receive Henry Schein ‘Comfort Kits’ appeared first on Myeloma Research News.

  • Keytruda Plus Standard Therapy Fails to Improve Outcomes in Multiple Myeloma
    by Joana Carvalho, MSc on September 9, 2019 at 1:51 pm

    The addition of Keytruda (pembrolizumab) to standard therapy — Revlimid (lenalidomide) or Pomalyst (pomalidomide) in combination with dexamethasone — failed to improve the clinical outcomes of patients with untreated or relapsed/refractory multiple myeloma, data from two Phase 3 trials show. Findings from the trials were published in the studies “Pembrolizumab plus lenalidomide and dexamethasone for […] The post Keytruda Plus Standard Therapy Fails to Improve Outcomes in Multiple Myeloma appeared first on Myeloma Research News.

Myeloma Research News The Web’s Daily Resource for Myeloma Research News

  • Investigational Antibody GBR 1342 Receives Orphan Drug Designation for Multiple Myeloma
    by Alejandra Viviescas, PhD. on September 20, 2019 at 12:46 pm

    GBR 1342, an investigational bispecific antibody developed by Glenmark Pharmaceuticals, was granted orphan drug designation by the U.S Food and Drug Administration (FDA) for the treatment of multiple myeloma patients who have received prior therapies. The FDA’s Office of Orphan Products Development (OOPD) gives this designation to novel therapies intended to improve the treatment and management […] The post Investigational Antibody GBR 1342 Receives Orphan Drug Designation for Multiple Myeloma appeared first on Myeloma Research News.

  • Ygalo Continues to Show Promising Activity in Relapsed, Refractory Multiple Myeloma
    by Joana Carvalho, MSc on September 18, 2019 at 10:53 am

    Ygalo (melflufen) combination therapy continues to demonstrate promising results, without significant side effects, in patients with relapsed or refractory multiple myeloma, updated data from two clinical trials show. The findings were presented at the Society of Hematologic Oncology (SOHO) 2019 Annual Meeting, held Sept. 11–14 in Houston, Texas. Ygalo is a lipophilic peptide-conjugated alkylator developed […] The post Ygalo Continues to Show Promising Activity in Relapsed, Refractory Multiple Myeloma appeared first on Myeloma Research News.

  • Researchers Identify Promising Target for CAR T-cell Therapy in Myeloma
    by Marta Figueiredo on September 13, 2019 at 1:33 pm

    Designing CAR T-cells to specifically target GPRC5D — a protein appreciably present on the surface of myeloma cells — may be a safe and effective therapy against multiple myeloma, a preclinical study shows. The study, “GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells,” was published in the journal […] The post Researchers Identify Promising Target for CAR T-cell Therapy in Myeloma appeared first on Myeloma Research News.

  • Cancer Patients Around the World to Receive Henry Schein ‘Comfort Kits’
    by Patricia Inacio, PhD on September 11, 2019 at 12:32 pm

    Henry Schein, a foundation devoted to promoting dental and medical health, has produced more than 27,000 comfort kits for people fighting cancer in the U.S. The kits, which are meant to make patients feel at home while receiving care away from home, were assembled by more than 2,100 Team Schein Members (TSM) globally. They will be given […] The post Cancer Patients Around the World to Receive Henry Schein ‘Comfort Kits’ appeared first on Myeloma Research News.

  • Keytruda Plus Standard Therapy Fails to Improve Outcomes in Multiple Myeloma
    by Joana Carvalho, MSc on September 9, 2019 at 1:51 pm

    The addition of Keytruda (pembrolizumab) to standard therapy — Revlimid (lenalidomide) or Pomalyst (pomalidomide) in combination with dexamethasone — failed to improve the clinical outcomes of patients with untreated or relapsed/refractory multiple myeloma, data from two Phase 3 trials show. Findings from the trials were published in the studies “Pembrolizumab plus lenalidomide and dexamethasone for […] The post Keytruda Plus Standard Therapy Fails to Improve Outcomes in Multiple Myeloma appeared first on Myeloma Research News.